Loading
Life sciences · Journal article
Memo - Magazine of European Medical Oncology · September 28, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Summary Adjuvant treatment of colorectal cancer (CRC) has traditionally been based on fluoropyrimidine- and oxaliplatin-based chemotherapy regimens, which remain the cornerstone of care for patients with resected stage III and selected high-risk stage II disease. However, despite substantial improvements in disease-free (DFS) and overall survival (OS), a considerable proportion of patients experience disease recurrence. More recently, attention has shifted toward novel adjuvant strategies aimed at further reducing the recurrence risk, including structured exercise, biomarker-guided aspirin therapy, immune checkpoint inhibition in mismatch repair-deficient (dMMR) CRC, and circulating tumor DNA (ctDNA)-based detection of molecular residual disease. The CHALLENGE trial demonstrated that a 3-year structured exercise intervention after completion of adjuvant chemotherapy significantly improves DFS and OS in patients with stage III and high-risk stage II colon cancer. The ALASCCA trial established low-dose aspirin as a promising precision medicine strategy in patients with phosphatidylinositol 3‑kinase (PI3K) pathway alterations. The ATOMIC trial provided the first phase III evidence supporting adjuvant immunotherapy in patients with dMMR stage III colon cancer. In parallel, ctDNA has emerged as a powerful prognostic marker, although randomized studies have also demonstrated that ctDNA-guided escalation or de-escalation cannot yet be considered a universal replacement for standard clinicopathological decision-making. This review summarizes the biological rationale, clinical background, pivotal phase III data, practical implementation, and remaining uncertainties of these emerging strategies.